Eva Pharma Launches Local Cancer Drug Production Facility in Egypt

Eva Pharma has launched a new oncology and hematology division, marking a step in Egypt’s strategy to localize the production of advanced cancer treatments and strengthen pharmaceutical self-sufficiency.
Built to EU-GMP standards, the new Eva Pharma for Oncology facility has an annual production capacity of 22 million packages, with seven cancer and immunotherapy drugs already available in the local market. The company plans to introduce 11 new treatments and expand exports to regional and international markets.
According to the Ministry of Health, Egypt’s oncology centers receive around 360,000 cancer cases annually, including 80,000 patients covered under the universal health insurance system, with annual treatment costs reaching nearly EGP 13 billion. Between 2017 and 2022, 366,823 cases and 95,275 deaths were recorded, highlighting the need for locally manufactured, affordable therapies.
Egypt currently operates 2,700 pharmaceutical production lines across 179 drug factories, in addition to facilities for biologics, medical supplies, and veterinary products.
The ministry described the launch as part of a broader plan to achieve drug security, encourage research and innovation, and position Egypt as a regional hub for advanced pharmaceutical manufacturing in the Middle East and Africa.